Oncocyte Price Target Raised to $4.25/Share From $3.60 by Needham

Oncocyte Price Target Raised to $4.25/Share From $3.60 by Needham

Dow JonesApr 25 02:50

Oncocyte Is Maintained at Buy by Needham

Oncocyte Is Maintained at Buy by Needham

Dow JonesApr 25 02:50

Needham: Maintaining the OncoCyte (OCX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.60 to $4.25.

Needham: Maintaining the OncoCyte (OCX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $3.60 to $4.25.

Zhitong FinanceApr 25 02:40

Needham Maintains Buy on OncoCyte, Raises Price Target to $4.25

Needham analyst Mike Matson maintains OncoCyte with a Buy and raises the price target from $3.6 to $4.25.

Analyst UpgradesApr 25 02:40

Strong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial Efficiency

TipRanksApr 24 22:45

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

GainersImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion. Nuwellis (NASDAQ:NUWE) shares increased by

BenzingaApr 23 20:06